Angitia Raises $130M Series D to Advance Bone-Building Bispecific…

Team S · 2026-02-06T14:13:01.000Z

Angitia Biopharmaceuticals, a clinical-stage biotech developing novel therapies for serious skeletal diseases, has raised $130 million in a Series D financing round its second megafundraise in just 14 months. The capital will support the advancement of the company’s pipeline of bone-building candidates including bispecific antibodies targeting key regulators of bone formation and resorption, with multiple programs progressing into Phase 2 and Phase 3 clinical studies. This Series D round saw Frazier Life Sciences and Venrock Healthcare Capital Partners co-lead the financing, bringing substantial institutional backing to Angitia’s musculoskeletal disease strategy. Participation also came from Ascenta Capital, BVF Partners, Logos Capital, RA Capital Management, and Wellington Management, alongside returning supporters such as Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Health Investment, Hillhouse Investment, Legend Capital, Morningside Group, OrbiMed, TF Capital and Yonghua Capital. The funds will be applied to further clinical expansion of flagship programs, including a recombinant BMP-6 candidate and bispecifics designed to enhance bone mineral density and tackle conditions like osteoporosis and osteogenesis imperfecta. Angitia’s pipeline is led by AGA111, currently in Phase 3 for spinal fusion patients, while AGA2118 and AGA2115 bispecific antibodies targeting sclerostin and DKK1 regulators of Wnt signaling are advancing through Phase 2 studies. The dual-target approach could offer significant improvements over existing osteoporosis treatments by both promoting bone formation and reducing bone loss.

Member Login Get Access

Angitia Raises $130M Series D to Advance Bone-Building Bispecific… | Newnex